Drug Drug Interactions with VICTRELIS® (boceprevir) Informative ...

Class of
Drug
6
ANTIARRHyTHMICS
Substrate
class
Drug Brand name (non
exhaustive list,
generics not listed).
For a complete list,
please consult
www.bcfi.be or
www.cbip.be
Amiodarone Cordarone ® Potential
Interaction
Sotalol Sotalex ® Potential
Interaction
Digoxin Lanoxin ® Potential
Interaction
Lidocaine Xylocard ® Potential
Interaction
Flecainide Tambocor ® , Apocard ® Potential
Interaction
Liverpool University (*) /
Extra-information
May
[amiodarone]*
AUC and Cmax of
Digoxin by 19%
and 18% b
May
[lidocaine]*
Recommendations SmPC/
Scientific Literature
Use with caution.
Monitor concentrations
of amiodarone*
Caution should
be exercised with
medicines known to
prolong the QT interval*
No dose adjustment
of digoxin or BOC is
recommended. Patients
receiving digoxin
should be monitored
appropriately †
Use with caution -
Clinical monitoring is
recommended*
May [flecainide]* Monitor the plasma
concentration of
Flecainide. Use with
caution*
smpc: A clinical drug
interaction study with digoxin
demonstrated that BOC is a
mild P-gp inhibitor in vivo,
increasing digoxin exposure
by 19%. An increase in plasma
concentrations of substrates
of the P-gp efflux transporter,
such as digoxin or dabigatran,
should be anticipated. No
dose adjustment of digoxin or
BOC is recommended. Patients
receiving digoxin should be
monitored appropriately
CYP pathway(s)
(www.cbip/bcfi.be)
(www.mims.com.au)
CYP3A4
Substrate/
Inhibitor/
Inducer
CYP3A4 Inhibitor +
Substrate
CYP3A4 Substrate of
P-gp
CYP2D6 Substrate